Hmmm - let's see. Cantor Fitzgerald's analyst has just come out with a note, having read the docs, to say that not only does he think MSB will get approval, from what he's read, but approval without further any further trials required, for pediatric GVHD use. He thinks further trials will be required for use in adults (ie: which isn't what this trial was for) but not kids.
So, it seems like if people actually understood what the release said, that it was a positive not a negative, from how I've read Cantors note. Which makes todays selling very, very strange... But let's see.
MSB Price at posting:
$3.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)